Document Type : Original Article(s)
Authors
1 Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 Department of Hematology and Oncology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Abstract
Background: Ovarian function suppression (OFS) plays a vital role in the treatment of premenopausal hormone-positive breast cancer patients. Still, some patients experience incomplete ovarian function suppression. Therefore, we aimed to investigate the prevalence of incomplete OFS in premenopausal hormone-positive breast cancer patients and identify associated risk factors.
Method: This cross-sectional study was conducted at Javad Al-Aeme Clinic from January to February 2024.We enrolled premenopausal hormone-positive breast cancer patients aged 18 to 55 who had been treated with a Gonadotropin-releasing hormone agonist (GnRH agonist) combined with an aromatase inhibitor for at least three months. The relationship between incomplete OFS and variables including age, body mass index (BMI), treatment duration, and type of GnRH agonist was analyzed. All statistical analyses were performed using Stata version 17.
Results: A total number of 47 patients, with a mean age of 43.36 years (standard deviation (SD) 5.55) 5.55) and a mean BMI of 26.88 kg/m² (SD 4.22) participated in this study. Among these patients, 23 (49%) had estradiol levels greater than 20 pg/ml, indicating incomplete OFS. Although no significant relationship was found between the variables and ovarian escape, the odds for ovarian escape were higher in younger patients and those with a higher BMI. Patients treated with goserelin at doses of 3.6 mg and 10.8 mg exhibited similar odds of ovarian escape, both of which were higher than those observed in patients treated with triptorelin 3.75 mg.
Conclusion: The high prevalence of incomplete OFS highlights the importance of monitoring ovarian function in high-risk pre-menopausal hormone-positive breast cancer patients.
Highlights
Naeem Nikpour (google scholar)
Keywords
Main Subjects
Please cite this article as: Kheirmand Parizi A, Nejadheidari A, Nikpour N, Nejadheidari F. Investigating ovarian function in pre-menopausal estrogen receptor-positive breast cancer: A cross-sectional study. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.106922.2276.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382-92. doi: 10.1016/S1470-2045(21)00758-0. Erratum in: Lancet Oncol. 2022;23(4):e161. doi: 10.1016/S1470-2045(22)00132-2. PMID: 35123662; PMCID: PMC8885431.
- Kucherov A, Polotsky AJ, Menke M, Isaac B, McAvey B, Buyuk E, et al. Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. Fertil Steril. 2011;95:2063-6. doi: 10.1016/j.fertnstert.2011.01.158. PMID: 21353673; PMCID: PMC3080458.
- Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:331-57. doi: 10.6004/jnccn.2024.0035. PMID: 39019058.
- Hetemäki N, Mikkola TS, Tikkanen MJ, Wang F, Hämäläinen E, Turpeinen U, et al. Adipose tissue estrogen production and metabolism in premenopausal women. J Steroid Biochem Mol Biol. 2021;209:105849. doi: 10.1016/j.jsbmb.2021.105849. PMID: 33610799.
- Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41:1376-82. doi: 10.1200/jco.22.01064. PMID: 36521078; PMCID: PMC10419413.
- Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016;34:1584-93. doi: 10.1200/jco.2015.61.2259. PMID: 26729437; PMCID: PMC4872316.
- Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, et al. Measuring ovarian escape in premenopausal estrogen receptor-positive breast cancer patients on ovarian suppression therapy. Oncologist. 2021;26:e936-e42. doi: 10.1002/onco.13722. PMID: 33594769; PMCID: PMC8176991.
- Chen Y, Zhang R, Yan Y, Li H, Song G. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study. Breast Cancer Res Treat. 2024;206:543-50. doi: 10.1007/s10549-024-07323-9. PMID: 38709374; PMCID: PMC11208182.
- Fleege NMG, Li Y, Kidwell KM, Henry NL. Ovarian function suppression in premenopausal women with concurrent endocrine therapy use. Clin Breast Cancer. 2023;23:454-60. doi: 10.1016/j.clbc.2023.03.009. PMID: 37076363.
- Lin J, Ouyang Y, Li Y, Jin L, Li S, Liu Y, et al. Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer. J Natl Cancer Inst. 2024;116:1587-97. doi: 10.1093/jnci/djae115. PMID: 38833681.
- Yiming L, Lei F, Miao M, Zhimin S, Keda Y. Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: A retrospective analysis. China Oncology. 2022;32:705-11.
- Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19:6389-97. doi: 10.1158/1078-0432.Ccr-13-0838. PMID: 24298069; PMCID: PMC3878717.
- Dowsett M, Lønning PE, Davidson NE. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. J Clin Oncol. 2016;34:1580-3. doi: 10.1200/jco.2015.62.3728. PMID: 26729430.
- Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27:3192-7. doi: 10.1200/jco.2008.18.6213. PMID: 19380451.
- Tesch ME, Zheng Y, Rosenberg SM, Poorvu PD, Ruddy KJ, Tamimi R, et al. Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy. NPJ Breast Cancer. 2024;10:67. doi: 10.1038/s41523-024-00680-0. PMID: 39090124; PMCID: PMC11294545.
- Mandic S, Kratzsch J, Mandic D, Debeljak Z, Lukic I, Horvat V, et al. Falsely elevated serum oestradiol due to exemestane therapy. Ann Clin Biochem. 2017;54:402-5. doi: 10.1177/0004563216674031. PMID: 27687081.
- Coyne K, Silverman P, Liu JH. Oral GnRH antagonist ovarian suppression after escape from GnRH agonist in breast cancer patients. Clin Breast Cancer. 2020;20:e551-e4. doi: 10.1016/j.clbc.2020.05.011. PMID: 32616435.
- Ohlsson B. Gonadotropin-releasing hormone and its role in the enteric nervous system. Front Endocrinol (Lausanne). 2017;8:110. doi: 10.3389/fendo.2017.00110. PMID: 28638366; PMCID: PMC5461264.
- Kendzierski DC, Schneider BP, Kiel PJ. Efficacy of different leuprolide administration schedules in premenopausal breast cancer: A retrospective review. Clin Breast Cancer. 2018;18:e939-e42. doi: 10.1016/j.clbc.2018.04.005. PMID: 29747931.
)